For adults with fatty liver disease, eating all meals within an 8-hour window each day leads to more weight loss and lower body mass index over 12 weeks compared to spreading the same number of calories throughout the day, even when total food intake is identical.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether 16:8 time-restricted eating consistently produces greater weight and BMI reduction than matched-calorie standard eating across diverse populations with MASLD, accounting for adherence, duration, and baseline metabolic health.
A systematic review and meta-analysis of all randomized controlled trials comparing 16:8 TRE versus isocaloric standard eating in adults with MASLD, including at least 10 studies with 500+ participants total, measuring weight and BMI change over 8–24 weeks, with standardized definitions of adherence and subgroup analyses by baseline BMI, insulin resistance, and sex.
Whether 16:8 TRE causes greater weight loss than matched-calorie standard eating in MASLD over 24 weeks, with blinding of outcome assessors and objective adherence monitoring.
A multicenter, double-blind, parallel-group RCT of 200 adults with MASLD (BMI 28–40 kg/m²), randomized to 16:8 TRE or matched-calorie standard eating for 24 weeks, with daily food logs, wearable activity trackers, and weekly telehealth check-ins; primary outcome: percentage change in body weight measured by DXA at 24 weeks.
Whether individuals with MASLD who adopt 16:8 TRE over 2 years experience sustained weight loss and reduced incidence of type 2 diabetes compared to those who follow standard dietary advice.
A prospective cohort study following 500 adults with MASLD for 2 years, stratified by adherence to 16:8 TRE (≥80% days) versus standard eating, measuring annual weight change, HbA1c, and incident diabetes, adjusting for baseline BMI, physical activity, and medication use.
Whether individuals with MASLD who achieved ≥5% weight loss via 16:8 TRE have a lower risk of developing advanced fibrosis over 5 years compared to those who lost similar weight via standard eating.
A case-control study comparing 100 MASLD patients with ≥5% weight loss via 16:8 TRE to 100 matched controls with similar weight loss via standard eating, assessing fibrosis progression via elastography over 5 years, with detailed dietary and behavioral history.
Whether adults with MASLD who currently practice 16:8 TRE have lower average body weight than those who do not, in a population-based sample.
A population-based cross-sectional survey of 2,000 adults with MASLD, measuring current eating patterns (TRE vs. standard) and body weight, adjusting for age, sex, income, and physical activity, to assess association.